The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
Oxford Immunotec intends to use the net proceeds from the offering for working capital and general corporate purposes.
The Department for International Trade Life Sciences Organisation (DIT LSO) and the China Britain Business Council (CBBC) will be hosting a delegation from the Future Health Industry Entrepreneurs Association (FHA) from China on the morning of Tue 5 Sep.
AMSBIO announces the launch of a new Hyaluronic Acid Quantification Kit, based on a highly specific and tightly binding protein to detect and measure Hyaluronic Acid, also known as Hyaluronan or HA.
Hermes Investment Management (Hermes), the £30.8 billion manager, has agreed to sell a 50% equity stake in Milton Park to Canada Pension Plan Investment Board (CPPIB) for approximately £200 million.
Isansys Lifecare Ltd is proud to announce it has been shortlisted for the Celebration of Innovation Awards 2017, a prestigious award celebrating the best of innovation in healthcare.
AMSBIO reports on an independent evaluation and use by I-Stem (Corbeil-Essonnes, France) of the Skeletal Muscle Differentiation kit - a cell culture media system to differentiate human stem cells into functional myotubes.
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.
PCI Pharma Services (PCI) has affirmed its position relative to the delayed enforcement of the US Food and Drug Administration (FDA)’s Compliance Policy for ‘Product Identified Requirements Under the Drug Supply Chain Security Act' (DSCSA).
Ipsen has cut the price of its kidney cancer Cabometyx to help secure its place within the NHS’ routine commissioning stream, helping to over-turn a previous decision that it did not represent value for money.
Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.